Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - metoprolol tartrate, quantity: 5 mg - injection - excipient ingredients: water for injections; sodium chloride - - intravenous therapy: disturbances of cardiac rhythm, in particular supraventricular tachyarrhythmias.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 25 mg - tablet, enteric coated - excipient ingredients: triethyl citrate; purified talc; sodium starch glycollate; magnesium stearate; maize starch; iron oxide yellow; calcium hydrogen phosphate dihydrate; methacrylic acid copolymer; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; lactose monohydrate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - diclofenac sodium, quantity: 50 mg - tablet, enteric coated - excipient ingredients: maize starch; methacrylic acid copolymer; colloidal anhydrous silica; magnesium stearate; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; purified talc; triethyl citrate; iron oxide yellow; titanium dioxide; lactose monohydrate; sodium starch glycollate - inflammatory and degenerative forms of rheumatism; rheumatoid arthritis; osteoarthritis. relief of acute or chronic pain states in which there is an inflammatory component. symptomatic treatment of primary dysmenorrhoea.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 35.121 mg (equivalent: sildenafil, qty 25 mg) - tablet, film coated - excipient ingredients: purified water; croscarmellose sodium; calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 140.483 mg (equivalent: sildenafil, qty 100 mg) - tablet, film coated - excipient ingredients: magnesium stearate; croscarmellose sodium; calcium hydrogen phosphate; microcrystalline cellulose; purified water; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sildenafil citrate, quantity: 70.241 mg (equivalent: sildenafil, qty 50 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; magnesium stearate; microcrystalline cellulose; purified water; croscarmellose sodium; titanium dioxide; hypromellose; triacetin; indigo carmine aluminium lake - vedafil is indicated for the treatment of erectile dysfunction in adult males. . vedafil is not indicated for use by women.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ketorolac trometamol, quantity: 30 mg - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; ethanol; sodium hydroxide; water for injections - short-term management of moderately severe, acute pain following surgical procedures. the total duration of ketorolac use should not exceed five days. it is recommended that parenteral ketorolac be used in the immediate postoperative period. patients can then be converted to an oral formulation (dependent on their analgesic needs). see dosage and administration, conversion from parenteral to oral therapy. the total period of treatment utilising the oral and/or intramuscular route of administration is not to exceed five days. general ketoral is not recommended for use as an obstetric preoperative medication or for obstetric analgesia because it has not been adequately studied for use in these circumstances and because of the known effects of drugs that inhibit prostaglandin biosynthesis on uterine contraction and fetal circulation. there is no satisfactory evidence for the use of ketoral in acute exacerbations of chronic painful inflammatory conditions (e.g. rheumatoid arthritis or osteoarthritis).

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - meloxicam, quantity: 15 mg - tablet, uncoated - excipient ingredients: magnesium stearate; sodium citrate dihydrate; pregelatinised maize starch; maize starch; microcrystalline cellulose; lactose monohydrate; colloidal anhydrous silica - symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - meloxicam, quantity: 7.5 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; maize starch; magnesium stearate; sodium citrate dihydrate; pregelatinised maize starch; microcrystalline cellulose; lactose monohydrate - symptomatic treatment of osteoarthritis and rheumatoid arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sumatriptan succinate, quantity: 140 mg (equivalent: sumatriptan, qty 100 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; magnesium stearate; titanium dioxide; macrogol 8000; hypromellose; triacetin; polydextrose - iptam tablets are indicated for the acute relief of migraine attacks with or without aura. there is no information available on the use of iptam in the treatment of basilar or hemiplegic migraines.